Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

SPRINTER
  NCT04732949		 RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedNA
309/314 inconclusive
  • inconclusive 2 % increase in clinical improvement (time to event analysis only),Recovery (time to event analysis only) (PE)
  • inconclusive 6 % increase in hospital discharge (PE)
Synairgen SG016
  NCT04385095		 RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedsome concern
50/51 suggested
  • suggested 1.3-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
  • suggested 2.2-fold increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons